A new connection with Genection

Invivoscribe launches new company to provide better, centralized genetic test offering

Kelsey Kaustinen
SAN DIEGO—In a move meant to provide better access to genetic testing forthe market as a whole, privately held Invivoscribe Technologies Inc. haslaunched Genection Inc., a personalized molecular medicine company.Genection will offer physicians a dedicated online platform for globalaccess to the clinically actionable genetic test menu, including routineand esoteric genetic tests, pharmacogenomics, cancer somatic mutationtesting and exome and whole-genome sequencing.

Genection is intendedto ease and improve both access to genetic tests and communication aboutthe process among all involved parties. The company's web applicationoffers HIPAA-compliant patient data management for physicians and healthorganizations, providing a secure method for clinicians to share testresults and genetic information with other healthcare providers.

"Inorder to make personalized molecular medicine a clinical reality, newplatforms need to be developed for the delivery of healthcare.Genection's mission seeks to accelerate this adoption process," Dr.Bradley Patay, chief medical officer at Genection, said in a pressrelease. "The combination of CLIA-validated genetic testing, whole-exomeor whole-genome sequencing and broad targeted assays, along withcritical bioinformatics, analytic tools and interpretative guidelineswill contribute to timely definitive diagnoses for patients with rare,unexplained diseases or complex diseases; in essence, this integrationwill speed delivery of genomic test results and improve patient care."

Thenew company's model is not payor driven, which will allow physiciansaccess to genetic tests that may be unavailable or inaccessible throughtheir patients' care plans and healthcare institutions. In addition tothe genetic test offering, Genection will also provide online ordering,advanced bioinformatics and linking of multiple CLIA- and CAP-accreditedlaboratories for reporting, interpretation and integrated servicesofferings.

Suzanne Graham, senior manager of business development forGenection, noted in a press release that the company's initial CLIA-and CAP-accredited laboratory partners include "ARUP Laboratories,Foundation Medicine, Cypher Genomics, the Laboratory for PersonalizedMolecular Medicine (LabPMM) in the U.S., as well as itsISO15189-compliant laboratory (LabPMM GmbH) in Martinsried, Germany."The company also has relationships with sequencing providers such asIllumina and Ambry Genetics and a consortium of genetic counselors.

"Genectionis a valuable tool in the personalized molecular medicine landscape.Clinicians spend too much of their time identifying and orderingclinically relevant genetic tests, while struggling to keep abreast ofthe flood of clinical information around new biomarkers," said Patay in astatement. "In addition to the broad selection of genetic testsavailable to order through their service, Genection offers one of themost relevant new genomic testing services next-generation sequencingused to detect driver mutations in cancer."

Genome sequencing costshave been dropping steadily in recent years, Genection notes on itswebsite, and highlights three primary areas in which personalizedmolecular testing is particularly advantageous: carrier testing forindividuals looking to become pregnant, cancer treatments and drugtreatments. Genection provides carrier testing for conditions such ascystic fibrosis, sickle cell anemia and Tay-Sachs disease, all of whichcan be tested for before pregnancy. Cancer testing can identifypatients' specific cancer types to enable more effective treatment, andpharmacogenomics-genetic testing to determine the efficacy of a drug andpredict potentially fatal reactions-can save lives, as Genection notesthat "adverse drug response is the sixth most common cause of death inthe United States."

In addition to its genetic test offering,Genection is also a gateway for the Together We Cure initiative, aglobal program that allows patients with acute myeloid leukemia andtheir physicians to share clinical information. As Genection explains onits website, "Together We Cure is the first initiative that provides aglobal portal promoting and providing access to comprehensive moleculartesting of each patient's cancer in order to accelerate our knowledgeand progress towards finding a cure." The information is shared in aHIPAA-compliant, anonymous manner.

Genection is a privately heldcompany owned by Invivoscribe Technologies. Invivoscribe's founder,chairman and CEO, Dr. Jeffrey E. Miller, will serve as Genection'spresident.




Kelsey Kaustinen

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

February 2023 Front Cover

Latest Issue  

• Volume 19 • Issue 2 • February 2023

February 2023

February 2023 Issue